Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Chemoembolization in Hepatocellular Carcinoma
NCT00049322Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2003
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Neovessel Formation as Measured by Angiogram at 14 weeks. Started Jun 2003; status: completed.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00049322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049322.